Related references
Note: Only part of the references are listed.HTA methodology and value frameworks for evaluation and policy making for cell and gene therapies
Doug Coyle et al.
EUROPEAN JOURNAL OF HEALTH ECONOMICS (2020)
Pembrolizumab for Previously Treated Advanced or Metastatic Urothelial Cancer: An Evidence Review Group Perspective of a NICE Single Technology Appraisal
Daniel Gallacher et al.
PHARMACOECONOMICS (2019)
Working together to deliver stratified medicine research effectively
S. G. Attar et al.
BRITISH MEDICAL BULLETIN (2019)
The RA-MAP Consortium: a working model for academia-industry collaboration
Andrew P. Cope et al.
NATURE REVIEWS RHEUMATOLOGY (2018)
Personalized Medicine and Pay for Performance: Should Pharmaceutical Firms be Fully Penalized when Treatment Fails?
Fernando Antonanzas et al.
PHARMACOECONOMICS (2018)
Consequences of Biomarker Analysis on the Cost-Effectiveness of Cetuximab in Combination with FOLFIRI as a First-Line Treatment of Metastatic Colorectal Cancer: Personalised Medicine at Work
Gerard Harty et al.
APPLIED HEALTH ECONOMICS AND HEALTH POLICY (2018)
Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma
J. Bellmunt et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Cost Implications of Value-Based Pricing for Companion Diagnostic Tests in Precision Medicine
Gregory S. Zaric
PHARMACOECONOMICS (2016)
Optimizing Trial Designs for Targeted Therapies
Thomas Ondra et al.
PLOS ONE (2016)
Some economics on personalized and predictive medicine
F. Antonanzas et al.
EUROPEAN JOURNAL OF HEALTH ECONOMICS (2015)
Genetic testing with primary prevention and moral hazard
David Bardey et al.
JOURNAL OF HEALTH ECONOMICS (2013)
Personalised, predictive and preventive medicine: a decision-theoretic perspective
Nils-Eric Sahlin et al.
JOURNAL OF RISK RESEARCH (2012)
REIMBURSEMENT AND VALUE-BASED PRICING: STRATIFIED COST-EFFECTIVENESS ANALYSIS MAY NOT BE THE LAST WORD
Neil Hawkins et al.
HEALTH ECONOMICS (2011)
Integrating predictive biomarkers and classifiers into oncology clinical development programmes
Robert A. Beckman et al.
NATURE REVIEWS DRUG DISCOVERY (2011)
Stratified cost-effectiveness analysis: a framework for establishing efficient limited use criteria
D Coyle et al.
HEALTH ECONOMICS (2003)
Share Paper
